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1 |  INTRODUCTION
In 1990, the Adenine to Guanine transition at position 3,243 of 
mitochondrial DNA (m.3243A>G) in the MT‐TL1 encoding 
tRNALEU(UUR) was found as the molecular basis for MELAS 
(Goto, Nonaka, & Horai, 1990; Kobayashi et al., 1990). The 
acronym MELAS was first used in 1984 by Pavlakis, Phillips, 
DiMauro, De Vivo, and Rowland (1984) to describe a group 
of patients with mitochondrial myopathy, encephalopathy, 
lactic acidosis, and stroke‐like episodes. As the m.3243A>G 
mutation is the most common cause of MELAS syndrome 
(MIM 540000), it is also reported as the MELAS mutation 
although other phenotypic expressions have been described. 
These include maternally inherited diabetes and deafness 
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Abstract
Background: The mitochondrial DNA m.3243A>G mutation is one the most preva-
lent mutation causing mitochondrial disease in adult patients. Several cohort studies 
have used heteroplasmy levels in urinary epithelial cells (UEC) to correlate the geno-
type of the patients to the clinical severity. However, the interpretation of these data 
is hampered by a lack of knowledge on the intra‐patient variability of the hetero-
plasmy levels. The goal of this study was to determine the day‐to‐day variation of the 
heteroplasmy levels in UEC.
Methods: Fifteen carriers of the m.3243A>G mutation collected five urine samples 
in a 14‐day window. Heteroplasmy levels of the m.3243A>G mutation were deter-
mined in these samples. Data from the national cohort study, including Newcastle 
Mitochondrial Disease Adult Scale scores and clinical diagnosis, were used.
Results: In the samples of six patients, heteroplasmy levels were within a 5% margin. 
In the samples collected from five patients, the margin was >20%.
Conclusion: Heteroplasmy levels of UEC in carriers of the m.3243A>G mutation 
have a significant day‐to‐day variation. The interpretation of a correlation between 
heteroplasmy levels in urine and disease severity is therefore not reliable. Therefore, 
heteroplasmy levels in UEC should not be used as a prognostic biomarker in these 
patients.
K E Y W O R D S
heteroplasmy, m.3243A>G, maternally inherited diabetes deafness, mitochondrial medicine, 
mitochondrial myopathy, encephalopathy, lactic acidosis and stroke‐like episodes, NMDAS, outcome 
measures
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(MIDD, MIM 520000) (Ouweland et al., 1992), hypertrophic 
cardiomyopathy (Lev et al., 2004), macular dystrophy (Laat, 
Smeitink, Janssen, Keunen, & Boon, 2013), gastrointestinal 
involvement (Laat et al., 2015),and oligosymptomatic vari-
ants of the acronym MELAS (Dvorakova et al., 2016). The 
m.3243A>G mutation is one the most prevalent pathogenic 
mutation of the mitochondrial DNA, prevalence being re-
ported in the range of 7.59–236/100,000 persons (Chinnery 
et al., 2000; Majamaa et al., 1998; Manwaring et al., 2007).
Since mitochondria and mitochondrial (mt) DNA are pres-
ent in all tissues except red blood cells, heteroplasmy percent-
ages can theoretically be assessed in virtually every tissue. 
Two problems arise when testing heteroplasmy: Most human 
tissues are practically not accessible and differences in het-
eroplasmy levels between samples might exist. For example, 
invasively obtained skeletal muscle tissue DNA usually gives 
higher and more consistent heteroplasmy levels than DNA ex-
tracted from a less invasively obtained blood sample (Rahman, 
Poulton, Marchington, & Suomalainen, 2001). The lower lev-
els in blood might even lead to false‐negative results (Laat 
et al., 2012). Previous studies showed a superiority of urine 
over blood as preferred noninvasive tissue for mutation anal-
ysis in patients at risk of carrying the m.3243A>G mutation 
(Frederiksen et al., 2006; Laat et al., 2012; Ma et al., 2009; 
Marotta et al., 2009). However, the relationship between muta-
tion load and clinical phenotype has been a subject of research 
for many years (Chinnery, Howell, Lightowlers, & Turnbull, 
1997; Grady et al., 2018; Liu et al., 2012; Nesbitt et al., 2013).
Surprisingly in several studies, including one of ourselves, 
a relationship between heteroplasmy levels in urinary epithe-
lial cells (UEC) and clinical symptoms was suggested. In 
these small sample sizes, the reported correlation coefficients 
were however rather low (Laat et al., 2012; Ma et al., 2009; 
Nesbitt et al., 2013; Whittaker et al., 2009). There is little 
evidence on whether heteroplasmy levels (in any tissue) cor-
relate with progression of the mitochondrial disease. A recent 
study showed an association between disease progression and 
age‐adjusted heteroplasmy in blood (Grady et al., 2018). In 
the other mentioned cohort studies, UEC’s have predomi-
nantly been investigated as a prognostic marker for severity 
of disease and disease progression. In this study, we show that 
the measurement of m.3243A>G UEC heteroplasmy levels 
have a large intra‐patient day‐to‐day variability. Cautiousness 
regarding the usage of m.3243A>G heteroplasmy levels in 
UEC as a prognostic biomarker as, for example, in drug in-
tervention studies is warranted.
2 |  METHODS
2.1 | Patients
All subjects were genetically diagnosed with the m.3243A>G 
mutation in DNA extracted from skeletal muscle and/or blood. 
They all participate in our natural history cohort study (Laat 
et al., 2012). The ethics committee of the Nijmegen‐Arnhem 
region approved this study. Written informed consent accord-
ing to the Helsinki agreement was obtained from all patients.
Patient characteristics regarding age, sex, and clinical 
 expression of the m.3243A>G were extracted from the data of 
the national cohort study, including Newcastle Mitochondrial 
Disease Adult Scale (NMDAS)‐scores, and mtDNA hetero-
plasmy levels in other tissues. All patients were asked to 
 report symptoms of urinary tract infections, fever, smoking, 
and alcohol use.
2.2 | Urine sample collection and 
mutation analysis
All patients received an isolation box with 5 urine contain-
ers. They were instructed to collect five urine samples in a 
14‐day window. The urine samples were to be collected in 
the morning of days 1, 4, 7, 10, and 13. The samples were 
stored at 3–6°C and send with regular postal service to the 
laboratory in the provided isolation box after collection of 
the fifth sample. DNA was isolated from the urine samples, 
after centrifugation of the urine for 10 min at 3,000 rpm, and 
the pellet was washed with phosphate‐buffered saline. DNA 
was extracted using a commercially available DNA isolation 
kit (PuregeneTM DNA isolation kit; Gentra Systems, MN).
Heteroplasmy levels were determined in all urine samples 
using PyrosequencingTM technology (Pyrosequencing, Uppsala, 
Sweden) as earlier described by Lowik, Hol, Steenbergen, 
Wetzels, and van den Heuvel (2005). The pyrosequencing reac-
tion of the m.3234A>G mutation had a precision of 1.5%, and 
the lowest limit of detection was 5%. The detection limit for the 
m.3243A>G mutation was determined by serial dilutions of a 
sample containing this mutation with wild‐type mtDNA.
2.3 | Statistics
We used descriptive statistics in analyzing the data.
3 |  RESULTS
3.1 | General patient characteristics
Fifteen carriers were included in the study (Table 1). Four 
carriers (27%) were male. Median age was 39 years (range: 
20–69 years). Patients had different phenotypic expressions 
of the m.3243A>G mutation: MELAS syndrome (one pa-
tient), MIDD (seven patients), isolated myopathy and fa-
tigue (four patients), and cardiomyopathy (one patient). 
The remaining two patients were clinically asymptomatic 
and should be categorized as dormant carriers. The median 
NMDAS score was 8 (range: 1–56 with 1 being the least se-
vere disease expression).
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3.2 | Heteroplasmy levels
A total of 75 urine samples were collected. In two samples, 
it was not possible to extract sufficient amounts of DNA for 
heteroplasmy analysis. Heteroplasmy level measurement 
was successful in the remaining 73 samples (Table 1). In the 
samples of six patients (Patients: 1, 2, 3, 4, 14, and 15), heter-
oplasmy levels were within 5% margin of each other (Figure 
1a). In the samples of five patients (Patients: 5,6,7,9, and 13), 
the margin was >20% (Figure 1b). In the remaining four pa-
tients (patients: 8, 10, 11, and 12), the variation between the 
heteroplasmy levels in the different samples was between 5% 
and 20%.
Patients 9 and 12 reported some complaints of a viral 
upper airway infection during the first days. Patient 14 re-
ported to have smoked during all days. There was no alcohol 
usage among the patients.
4 |  DISCUSSION
Urinary epithelial cells have been identified as the most op-
timal noninvasive tissue for measurement of heteroplasmy of 
mtDNA mutations (Laat et al., 2012). Heteroplasmy levels in 
UEC have also been correlated with disease severity (Whittaker 
et al., 2009). In this study, we show that UEC m.3243A>G het-
eroplasmy levels within one patient might show important day‐
to‐day variations. Based on these results, we conclude that the 
level of UEC heteroplasmy should be cautiously interpreted in 
predicting disease severity and the results of intervention stud-
ies in carriers of the m.3243A>G mutation.
We hypothesize that the difference in heteroplasmy levels 
between the different urine samples from individual patients 
is caused by a variation in different types of (epithelial) cells 
in the urine samples. Previous studies extensively studied 
the different epithelial cells in random urine samples and 
report a broad variation in different kinds of epithelial cells 
between samples (Schumann, 1981). Due to a genetic bot-
tleneck, there is variation between the heteroplasmy levels 
of cells from different organs or tissues in one patient (Cree, 
Samuels, & Chinnery, 2009). If there is a larger proportion 
of the cells in a urine sample with a higher or lower hetero-
plasmy level compared to another sample, this could explain 
the differences reported in this study.
Patients with a very high or very low heteroplasmy level in 
UEC have a smaller range of heteroplasmy levels compared to 
patients with heteroplasmy levels in the middle range (Figure 
1a,b). This is consistent with our hypothesis that there is a 
variation in cell types in the different urine samples, a normal 
distribution of the variance can be expected.
As several cohort studies (Laat et al., 2012; Nesbitt et al., 
2013), including one of our own, have used the heteroplasmy 
levels in UEC to correlate the genotype of the patients to 
the clinical severity, it is essential to have studied the intra‐ 
patient variability of the heteroplasmy levels in UEC. Overall, 
the disease progression in carriers of the m.3243A>G muta-
tion has no significant day‐to‐day variation. The interpreta-
tion of a correlation between heteroplasmy levels in urine and 
 disease severity is therefore not reliable.
5 |  CONCLUSION
In this study, we demonstrated that the measurement of 
m.3243A>G heteroplasmy levels in UEC might have a sub-
stantial intra‐patient day‐to‐day variability. The use of UEC 
m.32343A>G heteroplasmy levels as a prognostic biomarker 
should be interpreted in light of these findings.
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F I G U R E  1  Every patient is represented by one line. (a) 
Heteroplasmy levels differ <5% between the different measurements. 
(b) Heteroplasmy levels differ >20%
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